Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK statement on ACCC Federal Court judgment
We are pleased with today’s decision in relation to the revised Voltaren Osteo Gel 1% packaging
-
GSK Australia reports 2018 results to ASIC
GSK has reported its 2018 results to the Australian Securities and Investment Commission (ASIC)
-
2019 GSK Award for Research Excellence open for nominations
Nominations for the 2019 GSK Award for Research Excellence are now open and close at midnight on 9 June 2019
-
Experts highlight impact on life after meningococcal disease for Australian survivors
Health experts and survivors have come together for World Meningitis Day to draw attention to the potential lifelong impact meningococcal
-
GSK puts Australian researchers on Discovery Fast Track
GSK will provide access to its expertise in research, platform technologies and compounds to researchers from Monash University
-
Christi Kelsey appointed General Manager, Australia Pharmaceuticals
GSK Australia announced today that Christi Kelsey has been appointed General Manager, succeeding Anne Belcher
-
Parents’ confusion about meningococcal strains and vaccines may leave Australian children and adolescents at risk
New research confirms that poor understanding of meningococcal disease and its different strains means the majority of Australian children
-
Anne Belcher to leave GSK Australia
General Manager to take up role within GSK in United States
-
Australian researchers revolutionising melanoma treatment receive major research award
Professor Georgina Long and Professor Richard Scolyer win GSK Award for Research Excellence 2018
-
Kozenis (tafenoquine) approved by the Australian TGA for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
-
GSK Australia commits to new Reconciliation Action Plan
GSK Australia today committed to a new Reconciliation Action Plan (RAP), launching the plan at events at its Melbourne and Sydney offices
-
Doctors encouraging middle-aged Aussie blokes to consider their prostate
MJA Insight article highlights consequences of nation’s most common prostate condition, Benign Prostatic Hyperplasia – BPH1
-
Australia responds to changing humanitarian need with pioneering new health education course
Deakin University in partnership with global healthcare company GSK and not-for-profit humanitarian organisation Save the Children
-
New treatment reimbursed for major breathing disorder
Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) - first, once-daily triple therapy for COPD reimbursed by the PBS
-
GSK statement on influenza vaccine supply for the 2018 season
Due to high take up of flu vaccination in the last two months, reflecting the importance Australians are placing on helping protect
-
Nominations open for prestigious GSK Award for Research Excellence
Nominations for GSK’s Award for Research Excellence are now open until 2 July 2018
-
GSK Australia reports 2017 results to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2017 results to the Australian Securities and Investment Commission (ASIC)
-
Discontinuation of Typherix adult vaccine
GSK has announced that Typherix [Salmonella typhi Vi polysaccharide vaccine] adult vaccine will be discontinued from supply and no longer
-
GSK launches Discovery Fast Track: Australian Challenge in search of early drug discovery partnerships with local researchers
GSK has launched its Discovery Fast Track Australian Challenge, a program designed to accelerate the translation of early-stage research
-
New report aims to broaden understanding of how new medicines are funded in Australia
GlaxoSmithKline Australia (GSK) and ViiV Healthcare (ViiV) have launched a new report as part of an initiative to raise understanding
